BioSpace News Archive

Vitalant, one of the largest national nonprofit blood banks, is declaring a critical shortage of blood.

Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 13, 2019 at 1:30 p.m. PT (4:30 p.m. ET).

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced the Phase III JAVELIN Bladder 100 study met its primary endpoint of overall survival (OS) at the planned interim analysis.

CANTEL MEDICAL CORP. (NYSE: CMD) announced today that George Fotiades, President and CEO, will be presenting at the 38th annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco

Allergan plc, announced that its Warner Chilcott and Watson subsidiaries have reached resolutions with all plaintiffs, including a class of direct purchasers, individual direct purchasers that previously opted out of the direct purchaser class, and a class of indirect purchasers of Loestrin 24 Fe and Minastrin 24 Fe, concluding the previously disclosed antitrust litigation in the U.S. District Court for the District of Rhode Island.

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that a Phase 2 study of its novel hepcidin mimetic PTG-300 in patients with hereditary hemochromatosis has been initiated

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 38th annual J.P. Morgan Healthcare Conference

Applied BioCode announced that it has received 510(k) Clearance from the U.S. Food and Drug Administration (FDA) for its BioCode® Respiratory Pathogen Panel (RPP) for use on the BioCode® MDx-3000 System.

Technavio has announced its latest market research report titled global amniotic membrane market 2020-2024

Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, announced the grant of options to purchase 110,963 shares of its common stock to eight new employees.